Lgals1 Protein — Galectin 1 is a protein involved in neurodegenerative disease processes. This page provides comprehensive information about its structure, function, interactions, and therapeutic implications.
Galectin-1 (LGALS1) is a member of the galectin family of carbohydrate-binding proteins that recognize β-galactoside moieties. Unlike classical secreted proteins, galectin-1 lacks a signal peptide and is released through a non-classical pathway. This protein plays critical roles in immune regulation, neuronal development, and has emerged as an important modulator of neuroinflammation and neurodegenerative disease pathogenesis.
Galectin-1 has a distinctive structure:
- Carbohydrate Recognition Domain (CRD): ~130 amino acids for β-galactoside binding
- N-terminal Region: Involved in dimerization
- Dimeric Form: Functional unit (homodimer)
- Conserved Sequence: WXXERXR motif for carbohydrate binding
The protein forms a β-sandwich structure with the carbohydrate-binding site in a shallow groove.
- T-cell regulation (promotes Th2, inhibits Th1)
- Induces apoptosis in activated T-cells
- Macrophage polarization to anti-inflammatory phenotype
- Cytokine production modulation
- Axon guidance during development
- Neurite outgrowth promotion
- Synapse formation and plasticity
- Neuronal survival under stress
- Modulates cell adhesion molecules
- Regulates extracellular matrix interactions
- Controls glycoprotein turnover
Galectin-1 shows dynamic expression:
| Cell Type |
Expression Level |
| Neurons |
High (specific subtypes) |
| Astrocytes |
High |
| Microglia |
Moderate |
| Schwann Cells |
High |
| Immune Cells |
Variable (activation-dependent) |
In the nervous system, galectin-1 is upregulated during development, injury, and in disease states.
- Neuroinflammation: Modulates microglial activation
- Aβ clearance: May enhance phagocytosis
- Neuronal protection: Reduces amyloid toxicity
- Therapeutic potential: Galectin-1 mimetics
- Dopaminergic neuron protection: Reduces oxidative stress
- α-Synuclein interaction: May modulate aggregation
- Neuroinflammation: Immune regulatory effects
- Autoimmune regulation: Suppresses demyelination
- Remyelination: Promotes oligodendrocyte differentiation
- Clinical trials: Recombinant galectin-1 in MS
¶ Stroke and Brain Injury
- Neuroprotection: Reduces infarct size
- Anti-inflammatory: Limits post-injury inflammation
- Promotes recovery: Enhances neurorepair
Galectin-1 binds:
- N-acetyllactosamine (LacNAc)
- Lactose (β-D-Gal-(1→4)-D-Glc)
- Polylactosamine chains
- Complex N-glycans
- CD45, CD71 on T-cells
- Neuropilin-1 on neurons
- Integrins (cell adhesion)
- Lamp proteins
- Ras-ERK: Neurite outgrowth
- Akt: Cell survival
- p38 MAPK: Inflammatory response
Galectin-1-targeting strategies:
- Recombinant protein administration
- Small molecule agonists/antagonists
- Gene therapy vectors
- Cell-permeable peptides
- Multiple Sclerosis: Phase I/II trials
- Stroke: Neuroprotective strategies
- Autoimmune disorders: Immunomodulation
- Nerve injury: Regeneration promotion
| Model |
Findings |
| LGALS1 Knockout |
Enhanced T-cell proliferation, altered immunity |
| Transgenic LGALS1 |
Neuroprotection in stroke models |
| EAE (MS model) |
Reduced disease severity |
The study of Lgals1 Protein — Galectin 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.